December 12, 2011
Takeda Pharmaceutical announced on December 9 that the European Commission (EC) has granted marketing authorization for Edarbi (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB). Takeda will launch the product across Europe in 2012 starting with Germany in January...read more